192 related articles for article (PubMed ID: 1716430)
1. Clinical applications of serum tumor markers.
Bates SE
Ann Intern Med; 1991 Oct; 115(8):623-38. PubMed ID: 1716430
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
3. The use of serum tumor markers in the management of patients with malignancy.
Markman M
J Cancer Res Clin Oncol; 1993; 119(11):635-6. PubMed ID: 7688748
[No Abstract] [Full Text] [Related]
4. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
5. Serum (circulating) tumor markers for breast cancer.
Hayes DF
Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor markers in gynecologic oncology.
Olt G; Berchuck A; Bast RC
Obstet Gynecol Surv; 1990 Sep; 45(9):570-7. PubMed ID: 1697940
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers.
Pandha HS; Waxman J
QJM; 1995 Apr; 88(4):233-41. PubMed ID: 7540924
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.
Chigira M; Shinozaki T
Arch Orthop Trauma Surg; 1990; 109(5):247-51. PubMed ID: 1702981
[TBL] [Abstract][Full Text] [Related]
9. Pros and cons of gynecologic tumor markers.
Bast RC; Hunter V; Knapp RC
Cancer; 1987 Oct; 60(8 Suppl):1984-92. PubMed ID: 2443235
[TBL] [Abstract][Full Text] [Related]
10. Interlaboratory surveys of the determination of tumour markers scatter and repeatability of the results.
Kruse R; Geilenkeuser WJ; Röhle G
Eur J Clin Chem Clin Biochem; 1993 Mar; 31(3):139-46. PubMed ID: 7683915
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
12. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
[TBL] [Abstract][Full Text] [Related]
13. Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers.
Amiri FS
Ren Fail; 2016; 38(4):530-44. PubMed ID: 26907957
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers in patients with chronic renal failure.
Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in clinical practice: a review focusing on common solid cancers.
Duffy MJ
Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
[TBL] [Abstract][Full Text] [Related]
18. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
19. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
20. Prospective investigation of tumor markers and risk assessment in early cancer screening.
Kobayashi T; Kawakubo T
Cancer; 1994 Apr; 73(7):1946-53. PubMed ID: 8137222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]